Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies
CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and...
17 hours ago
AI news: Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy
She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient...
1 day ago
Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more
He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a...
3 days ago
.png){kind=logo}
